Dihexa is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-12-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | Derived from angiotensin IV and modified for stability. |
| Proposed mechanism | c-Met/HGF pathway activation | Described as an HGF mimetic in experimental systems. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Name usage varies by supplier and publication. |
| Regulatory status | Not approved as a drug | Sold as a research chemical in some markets. |
| Human trial data | Limited or absent | Most evidence comes from preclinical studies. |
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
== See also == Bond number – Dimensionless number in fluid dynamicsPages displaying short descriptions of redirect targets Bound water – Thin layer of water surrounding mineral surfaces Capillary action through synthetic mesh Capillary fringe – Subsurface layer in which groundwater seeps up from a water table by capillary action Capillary pressure – Pressure between two fluids from forces between the fluids and tube walls Capillary wave – Wave on the surface of a fluid, dominated by surface tension Capillary bridges – Minimised surface of liquid connecting two wetted objectsPages displaying short descriptions of redirect targets Damp proofing – Type of moisture control in building construction Darcy's law – Equation describing the flow of a fluid through a porous medium Frost flower – Thin layer of ice extruded from a plant Frost heaving – Upwards swelling of soil during freezing Hindu milk miracle – 1995 alleged miracle incidentsPages displaying short descriptions of redirect targets Krogh model Porosimetry – Measurement and characterization of the porosity of a material Needle ice – Ice column formed when liquid groundwater rises into freezing air Surface tension – Tendency of a liquid surface to shrink to reduce surface area Washburn's equation – Equation describing the penetration length of a liquid into a capillary tube with time Young–Laplace equation – Describing pressure difference over an interface in fluid mechanics
=== Four Conditions === Oven-dry (OD) is defined as the condition of an aggregate where there is no moisture within any part of the aggregate. This condition can be achieved in a laboratory by heating the aggregate to 220 °F (105 °C) for a period of time. Air-dry (AD) is defined as the condition of an aggregate in which there are some water or moisture in the pores of the aggregate, while the outer surfaces of it is dry. This is a natural condition of aggregates in summer or in dry regions. In this condition, an aggregate will absorb water from other materials added to the surface of it, which would possibly have some impact on some characters of the aggregate. Saturated surface dry (SSD) is defined as the condition of an aggregate in which the surfaces of the particles are "dry" (i.e., they will neither absorb any of the mixing water added; nor will they contribute any of their contained water to the mix), but the inter-particle voids are saturated with water. In this condition aggregates will not affect the free water content of a composite material. The water adsorption by mass (Am) is defined in terms of the mass of saturated-surface-dry (Mssd) sample and the mass of oven dried test sample (Mdry) by the formula:
(ICH E6) Any board, committee, or other group formally designated by an institution to review biomedical research involving humans as subjects, to approve the initiation of and conduct periodic review of such research. (21CFR50.3) Intent to treat
===== PI 88788 ===== The vast majority of cultivars in the US have soybean cyst nematode resistance (SCN resistance), but rely on only one breeding line (PI 88788) as their sole source of resistance. (The resistance genes provided by PI 88788, Peking, and PI 90763 were characterized in 1997.) As a result, for example, in 2012 only 18 cultivars out of 807 recommended by the Iowa State University Extension had any ancestry outside of PI 88788. By 2020 the situation was still about the same: Of 849 there were 810 with some ancestry from PI 88788, 35 from Peking, and only 2 from PI 89772. (On the question of exclusively PI 88788 ancestry, that number was not available for 2020.) That was speculated to be in 2012—and was clearly by 2020—producing SCN populations that are virulent on PI 88788.
They couldn't play anymore, Neil couldn't do it anymore, but they still want to play." Lee told The Washington Post in November 2023 that he would not rule out performing with Lifeson again as Rush, saying, "It was nice to know that if we decide to go out, Alex and I, whether we went out as part of a new thing, or whether we just wanted to go out and play Rush as Rush, we could do that now." When asked in December 2023 by CBS News Sunday Morning if he and Lifeson had talked about continuing as Rush with a new drummer, Lee said, "Have we talked about it? Yeah. It's not impossible, but at this point, I can't guarantee it." Lifeson then expressed optimism about the band's future, stating that, "It's just not in our DNA to stop." Lifeson later said in a January 2024 interview that he was no longer interested in touring, citing arthritis and expressing doubt that he could perform as he did years ago. In May 2024, Lifeson said that he and Lee were playing songs together, but continued to rule out the possibility of ever going back on tour. He declared that he was "proud of the fact" that Rush "was over when it was over." Also in May 2024, Lee and Lifeson appeared together onstage at a Gordon Lightfoot tribute concert at Massey Hall in Toronto, where they joined Blue Rodeo performing Lightfoot's "The Way I Feel". An anthology box set, titled Rush 50, was released on March 21, 2025.
Sources: en.wikipedia.org
The Vermont Army National Guard and Vermont Air National Guard are collectively known as the Vermont National Guard or "Green Mountain Boys". Both units use the original Green Mountain Boys battle flag as their banner.
=== Glass production === The largest commercial use of selenium, accounting for about 50% of consumption, is for the production of glass. Selenium compounds confer a red color to glass. This color cancels out the green or yellow tints that arise from iron impurities typical for most glass. For this purpose, various selenite and selenate salts are added. For other applications, a red color may be desired, produced by mixtures of CdSe and CdS.
The HIV-1 PR precursor catalyzes its own production by facilitating its cleavage from the Gag-Pol polyprotein in a mechanism known as auto-processing. Auto-processing of HIV-1 PR is characterized by two sequential steps: (1) the intramolecular cleavage of the N-terminus at the p6pol-protease cleavage site, which serves to finalize PR processing and increase enzymatic activity with the newly formed PR-reverse transcriptase intermediate, and (2) the intermolecular cleavage of the C-terminus at the protease-reverse transcriptase cleavage site, leading to the assembly of two PR subunits into mature dimers. Dimerization of the two subunits allows for fully functional, combined active site, characterized by two Asp25 catalytic residues (one from each monomer), to form.
=== 19th century === Mary Watson (1856–1933), one of the first two female chemistry students at the University of Oxford Margaret Seward (1864–1929), one of the first two female chemistry students at the University of Oxford; signed the 1904 petition to the Chemical Society Vera Bogdanovskaia (1868–1897), one of the first female Russian chemists Martina Casiano y Mayor (1881–1958), first female member of the Spanish Society of Physics and Chemistry Gerty Cori (1896–1957) Jewish Czech-American biochemist who was the first American to win a Nobel Prize in science Margot Dorenfeldt (1895–1986) First woman to graduate from Norwegian Institute of Technology (1919) Ida Freund (1863–1914), first woman to be a university chemistry lecturer in the United Kingdom Ellen Gleditsch (1879–1968), Norwegian radiochemist; Norway's second female professor Louise Hammarström (1849–1917), Swedish mineral chemist, first formally educated female Swedish chemist Edith Humphrey (1875–1978), Inorganic chemist, probably the first British woman to gain a doctorate in chemistry Julia Lermontova (1846–1919), Russian chemist, first Russian female doctorate in chemistry Laura Linton (1853–1915), American chemist, teacher, and physician Rachel Lloyd (1839–1900), First American female to earn a doctorate in chemistry, first regularly admitted female member of the American Chemical Society, studied sugar beets Muriel Wheldale Onslow (1880–1932), British biochemist Marie Pasteur (1826–1910), French chemist and bacteriologist Mary Engle Pennington (1872–1952), American chemist Agnes Pockels (1862–1935), German chemist Anna Sundström (1785–1871), Swedish chemist Clara Immerwahr (1870–1915), First woman to get her doctorate in chemistry in Germany Ellen Swallow Richards (1842–1911), American industrial and environmental chemist Anna Volkova (1800–1876), Russian chemist Nadezhda Olimpievna Ziber-Shumova (died 1914), Russian chemist Fanny Rysan Mulford Hitchcock (1851–1936), one of thirteen (American) women to graduate with a degree in chemistry in the 1800s, and the first to graduate with a doctorate in philosophy of chemistry. Her areas of focus were in entomology, fish osteology, and plant pathology.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.
It is based on angiotensin IV, a naturally occurring peptide fragment, but dihexa itself is chemically modified and synthetic. The modifications aim to improve stability and activity compared with the parent fragment.
Laboratory studies have used cell-based assays and rodent models. These examine receptor signaling, dendritic spine changes, and behavioral tasks. Published human clinical trial data are lacking.
Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.